English 
Illumi Medical Co., Ltd. has completed its Series A funding round, raising a total of 550 million yen. The round was closed in multiple stages between October 2025 and early 2026. With this final close, the company now has the capital it needs to move its light based medical technology closer to real use.
The funding came from a mix of regional and institutional investors. These include NEX-T Tokai Innovation Fund, Meigin Venture Fund No. 1, Hokkoku Bank, and Japan Finance Corporation. The focus now shifts from development to execution.
Illumi Medical plans to use the funds to push product development forward and prepare for mass production. Building a stable supply system is also part of the plan, especially ahead of clinical trials. At the same time, the company is looking outside Japan. It is working on regulatory approvals and insurance strategies with overseas partners and pharmaceutical companies.
こちらもお読みください： 日台ヘルスケア・アライアンス、バイオテクノロジー革新とグローバル創薬に新たな勢い
Alongside this, イルミメディカル is expanding its pipeline. It is exploring how phototherapy can be applied to new areas, including neurological conditions. Hiring is also part of the plan, with a focus on regulatory, device development, and business roles to support global growth.
日本語